A randomized trial of a somatostatin analog for preserving beta cell function in children with insulin dependent diabetes mellitus.
In an attempt to rest the beta cells of newly diagnosed children with type I diabetes mellitus (IDDM) and thus possibly preserve beta cell function, ten children were given Octreotide, a somatostatin analog, for the first 21 days after diagnosis. Ten age-matched diabetic children served as controls. Although there were no differences in either insulin requirements or in hemoglobin A1 levels, there were significant increases in the glucagon-stimulated C-peptide levels of the experimental group at six and 12 months after diagnosis, compared to control patients.
Grunt
J A
JA
University of Missouri-Kansas City School of Medicine, USA.
al-Hakim
H
H
Willoughby
L
L
Howard
C P
CP
D000293:Adolescent; D001786:Blood Glucose / Q000378:metabolism; D002096:C-Peptide / Q000378:metabolism; D002648:Child; D002675:Child, Preschool; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy* / Q000503:physiopathology; D005934:Glucagon; D006441:Hemoglobin A / Q000378:metabolism; D006801:Humans; D007328:Insulin / Q000008:administration & dosage / Q000627:therapeutic use; D007515:Islets of Langerhans / Q000187:drug effects / Q000502:physiology*; D015282:Octreotide / Q000627:therapeutic use*
D001786:Blood Glucose; D002096:C-Peptide; D007328:Insulin; D005934:Glucagon; D006441:Hemoglobin A; D015282:Octreotide